Essential Biotechnology has a new approach to cancer therapy. It’s time to learn from the failures of the targeted molecular therapies of the past and go for the jugular. We have discovered a molecule that serves as a nexus in regulating tumor cell survival- allowing the tumor cells to survive the stresses of their environment and chemotherapies. We have developed monoclonal antibodies that target this nexus and kill cancer cells by making them sensitive to stress once again. Preclinical work has shown that this approach works, even on traditionally “undruggable” Ras-driven cancers. Ovarian, lung, and pancreatic cancers represent multi-billion dollar clinical problems with no adequate solutions in large part due to resistance to therapy. This is a new class of drug target with a novel mechanism of action that works in concert with existing drugs. We are seeking industry partners with compatible pipelines to help us bring these new antibodies into the clinic.